Literature DB >> 2278396

Determination of imipramine and seven of its metabolites in human liver microsomes by a high-performance liquid chromatographic method.

T B Zeugin1, K Brosen, U A Meyer.   

Abstract

The metabolism of the widely used antidepressant drug imipramine is subject to marked interindividual variation. A sensitive and specific reversed-phase high-performance liquid chromatography method for the simultaneous determination of imipramine and seven of its metabolites in human liver microsomal preparations was developed. These metabolites include 10-hydroxy-desipramine, 10-hydroxyimipramine, 2-hydroxydesipramine, 2-hydroxyimipramine, desipramine, didesmethylimipramine, and imipramine N-oxide. The detection limit for imipramine and the metabolites was approximately 20 pmol. At concentrations of 100 and 500 pmol per tube, the reproducibility showed a coefficient of variation less than 10%, except for the 2-hydroxy-desipramine (16%), 2-hydroxyimipramine (15%), and imipramine N-oxide (17%), all three at 100 pmol per tube. Linear standard curves were obtained for all the compounds within a concentration range of 50 to 1000 pmol per tube. This assay will provide a tool to assess the contribution of different enzymes to the formation of imipramine metabolites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2278396     DOI: 10.1016/0003-2697(90)90052-b

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  3 in total

1.  Inhibitors of imipramine metabolism by human liver microsomes.

Authors:  E Skjelbo; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; E Skjelbo
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.